Publications

Suppression of cancer relapse and metastasis by inhibiting cancer stemness
Youzhi Li, Harry A. Rogoff, Sarah Keates, Yuan Gao, Sylaja Murikipudi, Keith Mikule, David Leggett, Wei Li, Arthur B. Pardee, and Chiang J. Li December 23, 2014 PNAS 2015 ; Published on February 10, 2015
Cancer Stem Cells: Current Perspectives, Future Directions—a supplement to Oncology Times.
Interviews with: Max S Wicha, MD, and Jaffer Ajani, MD. This supplement provides current insights into the role of CSCs in tumor initiation, progression, and metastasis, with a focus on gastric and gastroesophageal tumors. The potential for inhibition of CSC signaling pathways is reviewed.
Cancer Stem Cells: The Promise and the Potential
This supplement updates clinicians on the accumulated evidence characterizing the role of CSCs in tumor initiation, heterogeneity, therapy resistance, and recurrence and metastasis, as well as the therapeutic potential of targeting CSCs. Jaffer Ajani, Shumei Song, Howard Hochster, and Ira Steinberg, guest editors.

Abstracts and Presentations

The following scientific and clinical research was published or presented at meetings hosted by the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).

MeetingTitle
2017 Gastrointestinal Cancers Symposium (ASCO GI), San Francisco, CABBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in K-ras wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) (Abstract)
2017 Gastrointestinal Cancers Symposium (ASCO GI), San Francisco, CACancer stemness inhibition and chemosensitization: Phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (bev) administered to colorectal cancer (CRC) patients (pts) (Abstract)
The 2016 ASCO Annual Meeting, Chicago, ILA phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer (Abstract) (Poster)
The 2016 ASCO Annual Meeting, Chicago, ILA Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer (Abstract) (Poster)
The 2016 ASCO Annual Meeting, Chicago, ILPhase I extension clinical study of BB503, a first-in-class cancer stemness kinase inhibitor, in adult patients with advanced head and neck cancer (Abstract) (Poster)
The 2016 ASCO Annual Meeting, Chicago, ILThe BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma (Abstract) (Poster)
The 2016 ASCO Annual Meeting, Chicago, ILA Phase Ib extension study of cancer stemness inhibitor BB608 (Napabucasin) in combination with Gemcitabine and nab-Paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer (Abstract) (Poster)
The 2016 ASCO Annual Meeting, Chicago, ILPhase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC) (Abstract) (Poster)
The 2016 ASCO Annual Meeting, Chicago, ILA Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Non-Small Cell Lung Cancer (Abstract) (Poster)
2016 Gastrointestinal Cancers Symposium (ASCO GI), San Francisco, CAPhase Ib study of cancer stem cell (CSC) pathway inhibitor BBI608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC) (Abstract) (Poster)
2016 Gastrointestinal Cancers Symposium (ASCO GI), San Francisco, CAA phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer (Abstract) (Poster)
2016 Gastrointestinal Cancers Symposium (ASCO GI), San Francisco, CAA phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) (Abstract) (Poster)
The 2015 ASCO Annual Meeting, Chicago, ILA phase 1 study of BBI608, a cancer stemness inhibitor, administered with paclitaxel (PTX) as combination therapy (Rx) for pretreated unresectable or recurrent gastric cancer in Japan (Abstract) (News Release)
The 2015 ASCO Annual Meeting, Chicago, ILBBI503-101: Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cance (News Release) (Poster)
The 2015 ASCO Annual Meeting, Chicago, ILBBI608-224: A phase 1b/2 study of cancer stemness inhibitor BBI608 administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer (News Release) (Poster)
The 2015 ASCO Annual Meeting, Chicago, ILBBI608-246: A phase 1b study of first-in-class cancer stemness inhibitor BBI608 in combination with FOLFIRI with and without bevacizumab in patients with advanced colorectal cancer (News Release) (Poster)
The 2015 ASCO Annual Meeting, Chicago, ILThe BRIGHTER trial: A phase 3 randomized, double-blind, placebo-controlled clinical trial of first-in-class cancer stemness inhibitor BBI608 plus weekly paclitaxel versus placebo plus weekly paclitaxel in adult patients with advanced, previously treated gastric and gastro-esophageal junction (GEJ) adenocarcinoma (News Release) (Poster)
The 2015 ASCO Annual Meeting, Chicago, ILBBI608-201: Phase 1b/2 study of cancer stemness inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma (News Release) (Poster)
AACR Annual Meeting 2015, Philadelphia, PAInhibition of Stemness by BBI608 is Sufficient to Suppress Cancer Relapse and Metastasis (Pre-clinical data) (Abstract) (News Release) (Poster)
The 2014 ASCO Annual Meeting, Chicago, ILA Phase 1 Dose-Escalation Study of BBI503, a First-In-Class Cancer Stemness Kinase Inhibitor in Adult Patients with Advanced Solid Tumors (Abstract) (News Release)
The 2014 ASCO Annual Meeting, Chicago, ILThe NCIC CTG and AGITG CO.23 Trial: A Phase III Randomized Study of BBI608 Plus Best Supportive Care (BSC) Versus Placebo (PBO) Plus BSC in Patients (Pts) with Pretreated Advanced Colorectal Carcinoma (CRC) (Abstract) (News Release)
The 2014 ASCO Annual Meeting, Chicago, ILA Phase 1 Dose-Escalation Study of BBI503, a First-In-Class Cancer Stemness Kinase Inhibitor in Adult Patients with Advanced Solid Tumors (Abstract) (News Release)
The 2014 ASCO Annual Meeting, Chicago, ILA Phase 1b Study of the Cancer Stem Cell Inhibitor BBI608 Administered with Paclitaxel in Patients with Advanced Malignancies (Abstract) (News Release)
AACR Annual Meeting 2014, San Diego, CASpecific and Potent Silencing of K-Ras by Asymmetric RNA Technology Reveals Addiction of Gastric Cancer Stem Cells (Abstract)
The 2013 ASCO Annual Meeting, Chicago, ILBBI608-101: A Dose-Escalation Phase I Study of a First-In-Class Cancer Stemness Inhibitor in Patients with Advanced Malignancies (News Release)
AACR Annual Meeting 2010, Washington, DCA Phase 1 Dose Escalation Study of BBI608, a First-in-class Cancer Stemness Inhibitor, in Patients with Advanced Malignancies (Abstract)

Join Our Team

We are looking for motivated, passionate and skilled scientists and commercial team members.Learn More